Introduction
Sudden unexplained/unexpected death (SUDEP) in epilepsy is a major cause of death accounting for 7-17% of the mortality among general epileptic population and for up 50% among patients with refractory epilepsy. 1 The molecular basis of SUDEP remains unclear although many potential patho-mechanisms have been suggested. Cardiac arrhythmias, electrolyte disturbances, administration of arrhythmogenie drugs and central or obstructive apnea are to date proposed as possible causes.
Prolongation of QT-interval has been issued as a major mechanism of cardiac arrhythmias-related SUDEP, and it may be precipitated by anti-epileptic treatment. 2 In a recent review article Stollberger and Finsterer 2 analyzed the strict relationship between anticonvulsant therapy and QT-prolongation. Surprisingly primidone was considered to be an agent with potential arrhythmogenic effect attributed to QT-lengthening. 2 This is in fact in straight contrast Seizure (2006) Summary Sudden unexplained/unexpected death (SUDEP) in epilepsy is a major cause of death accounting for 7-17% of the mortality among epileptic patients. Prolongation of QT-interval has been issued as a major mechanism in SUDEP since it is associated with fatal cardiac arrhythmias. This condition may be further precipitated by anti-epileptic treatment.
Despite thorough literature research, we did not find any reports suggesting that primidone is responsible for QT-prolongation. On the contrary, all the retrieved reports addressed that the drug shortened QT-interval and corrected signs and symptoms of the underlying disease. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
with the current knowledge, which considers primidone as the only anticonvulsant drug able to shorten QT-interval and correct cardiac arrhythmias. 3 Consequently, considering the importance of primidone therapy in epileptic patients with syncope and prolonged QT-interval, and the possible consequences of removing the only anti-epileptic compounds with the over mentioned characteristics, we performed a comprehensive review of literature.
Materials and methods
In order to retrieve studies analyzing the impact of primidone therapy on QTwe performed a systematic search of medical literature in four libraries (Cochrane, PubMed, EMBASE and ISI Science Citation Index) with the following searching algorithms:
QT AND (primidone OR mysoline) (QT length OR sudden death OR SUDEP) AND (primidone OR mysoline)
We set no year and no language restriction. In order to implement the literature-search feasibility, the reference list of retrieved papers was further screened for possible reports. Potentially eligible papers were selected by abstract or title. In case of doubts during the data processing from full-text reports, we personally contacted the first author for clarifications.
Results
Despite an extensive literature search we were able to retrieve only three eligible studies. [3] [4] [5] All of the studies were case reports, two manuscripts were in English and one in Chinese language. A total number of eight patients were available for analysis.
In all eight patients the administrations of primidone was followed by QT-shortening and symptoms remission (seizure, syncope, torsade des pointes, arrhytmia). The clinico-pathologic features of each patient are reported in Table 1 .
Discussion
Clinicians are often faced with cardiac arrhythmias accompanying epilepsy or complicating anti-epileptic therapy. QT-lengthening with torsades de pointes is a potentially fatal form of ventricular arrhythmia with increased incidence among patients suffering from epilepsy. This type of arrhythmia is precipitated by the administration of certain anticonvulsant agents. Primidone's favorable influence on QT-interval may offer an alternative in management of epilepsy and essential tremor when special arrhythmogenic considerations (as QT-prolongation with or without torsades de pointes) are taken into account. Despite literature is poor, we did not find any reports inculpating primidone for QT-lengthening, on the opposite, all the retrieved reports address that the drug shortened QT and corrected signs and symptoms of the underlying disease.
We thus disagree with the recent review of Stollberger and Finsterer 2 by the statement that primidone may be responsible for QT-prolongation. According to authors, the aforementioned conclusion stems from a case reported by Loukeris et al. 4 Loukeris et al. reported a case of severe hypocalcemia associated with chronic anticonvulsant therapy with sodium valproate and primidone. In that case, QT-prolongation was disproportionate for the degree of hypocalcemia and serum calcium correction accompanied by only a slight shortening QT-interval.
There is therefore the suggestion that primidone effect may be beneficial in QT-interval shortening; anyhow since only eight cases had been described in literature a firm conclusion may not be drawn. Due to the paucity of reports the mechanism of actions is not fully understood.
